Pharmaceutical - Financial, Roche

Filter

Current filters:

FinancialRoche

Popular Filters

1 to 25 of 36 results

Roche drops rights to Inovio’s prostate cancer candidate

17-11-2014

Swiss pharma major Roche has terminated its 2013 collaboration, option, and license agreement with US…

Anti-viralsFinancialINO-1800INO-5150Inovio PharmaceuticalsLicensingOncologyPharmaceuticalRoche

Roche to invest billions in new R&D facility and Basel updates

Roche to invest billions in new R&D facility and Basel updates

22-10-2014

Swiss pharma major Roche says it will invest 3 billion Swiss francs ($3.2 billion) in new research infrastructure…

FinancialGeography of EuropePharmaceuticalRocheSwitzerland

Roche posts solid sales performance for first nine months of 2014

Roche posts solid sales performance for first nine months of 2014

16-10-2014

Swiss pharma major Roche this morning released its financials for the first nine months of 2014, showing…

Economy of SwitzerlandFinancialPharmaceuticalRocheSwitzerlandtrastuzumab

Currency takes toll on Roche first-half results

Currency takes toll on Roche first-half results

24-07-2014

Swiss pharma major Roche, the world’s leading oncology company, this morning posted first-half 2014…

FinancialOncologyPharmaceuticalRocheSwitzerland

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

11-06-2014

The European Federation of Pharmaceutical Industries and Associations says it is concerned about a decision…

AvastinEuropeFinancialItalyNovartisOphthalmicsPharmaceuticalRegulationRoche

Avastin could save the USA $29 billion if used instead of Lucentis

Avastin could save the USA $29 billion if used instead of Lucentis

04-06-2014

Using Avastin (bevacizumab) from Swiss drug major Roche instead of Lucentis (ranibizumab) from fellow…

AvastinBevacizumabFinancialLucentisNovartisOphthalmicsPharmaceuticalRocheUSA

Roche starts 2014 with sales dip due to strong franc

Roche starts 2014 with sales dip due to strong franc

15-04-2014

Swiss pharma major Roche kicked of the 2014 financial results reporting season, posting a 1% dip in group…

FinancialPharmaceuticalRoche

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

06-03-2014

Swiss pharma majors Roche and Novartis colluded to exclude the cheaper cancer drug Avastin (bevacizumab),…

AvastinEuropeFinancialItalyLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Funding restrictions for rituximab and eltrombopag widened in New Zealand

Funding restrictions for rituximab and eltrombopag widened in New Zealand

20-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen…

Asia-PacificeltrombopagFinancialGlaxoSmithKlineHealthcareImmunologicalsNew ZealandPharmaceuticalrituximabRoche

Five big pharma firms named as high performers in annual biopharmaceutical report

Five big pharma firms named as high performers in annual biopharmaceutical report

12-02-2014

Entry in emerging markets and expedient product launches are still driving the pharma market, according…

AmgenAstellas PharmaBristol-Myers SquibbFinancialMarkets & MarketingNovo NordiskPharmaceuticalResearchRoche

Lung cancer treatment takes another forward step in New Zealand

Lung cancer treatment takes another forward step in New Zealand

09-01-2014

Improvements in lung cancer treatment are set to continue with a decision for New Zealand’s Pharmaceutical…

Asia-PacificAstraZenecaFinancialHealthcareIressaOncologyPharmaceuticalRocheTarceva

Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019

24-12-2013

The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

BIA warns that UK government pricing proposals would damage UK biotech

20-08-2013

The BioIndustry Association (BIA), the UK trade association for the innovative biotechnology sector,…

AvastinBayerEuropeEyleaFinancialLucentisPharmaceuticalPoliticsPricingRegeneronRoche

July a strong month for life sciences IPOs and M&A

05-08-2013

The life sciences initial public offering (IPO) market continued to heat up in July as six life sciences…

BiotechnologyCubist PharmaceuticalsFinancialMergers & AcquisitionsPerrigoPharmaceuticalRoche

Roche hopes Kadcyla will replace revenue lost by Herceptin patent expiry

02-08-2013

Swiss drug major Roche (ROG: SIX) could be hit by biosimilar versions of its breakthrough HER2-positive…

EuropeFinancialHerceptinKadcylaOncologyPharmaceuticalRoche

Strong 1st-half at Roche driven by cancer drug

25-07-2013

Swiss drug major Roche (ROG: SIX) has posted a health set of financial results for the first half of…

BiotechnologyFinancialPharmaceuticalRoche

Cheaper anti-cancer drug as effective as expensive disease-specific agent in treating wet AMD

21-07-2013

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness…

AvastinBiotechnologyEuropeFinancialLucentisNovartisOphthalmicsPharmaceuticalResearchRoche

PDL files for arbitration for alleged royalties underpayments by Genentech

11-06-2013

USA-based PDL BioPharma (Nasdaq: PDLI) revealed today (June 11) that it has filed a Notice of Arbitration…

BiotechnologyFinancialGenentechLegalPDL BioPharmaPharmaceuticalRoche

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone

19-04-2013

Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

Roche 1st-qtr 2013 sales grow 6%, driven by cancer drugs

11-04-2013

Swiss drug major Roche (ROG: SIX) this morning posted first-quarter 2013 sales figures, showing 6% (constant…

BiotechnologyFinancialPharmaceuticalRoche

HER2-positive breast cancer patients prefer faster subcutaneous administration of Herceptin to IV

15-03-2013

Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin)…

EuropeFinancialHealthcareHerceptinOncologyPharmaceuticalRegulationRoche

1 to 25 of 36 results

Back to top